Der CJ - Search Results

1

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.

Waters AM, Der CJ. Waters AM, et al. Among authors: der cj. Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a031435. doi: 10.1101/cshperspect.a031435. Cold Spring Harb Perspect Med. 2018. PMID: 29229669 Free PMC article. Review.

2

Aberrant function of the Ras signal transduction pathway in human breast cancer.

Clark GJ, Der CJ. Clark GJ, et al. Among authors: der cj. Breast Cancer Res Treat. 1995 Jul;35(1):133-44. doi: 10.1007/BF00694753. Breast Cancer Res Treat. 1995. PMID: 7612899 Review.

3

Ras family signaling: therapeutic targeting.

Cox AD, Der CJ. Cox AD, et al. Among authors: der cj. Cancer Biol Ther. 2002 Nov-Dec;1(6):599-606. doi: 10.4161/cbt.306. Cancer Biol Ther. 2002. PMID: 12642680 Free article. Review.

4

Targeting signal transduction in pancreatic cancer treatment.

Yeh JJ, Der CJ. Yeh JJ, et al. Among authors: der cj. Expert Opin Ther Targets. 2007 May;11(5):673-94. doi: 10.1517/14728222.11.5.673. Expert Opin Ther Targets. 2007. PMID: 17465725 Review.

5

Ras-driven transformation of human nestin-positive pancreatic epithelial cells.

Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, Der CJ. Campbell PM, et al. Among authors: der cj. Methods Enzymol. 2008;439:451-65. doi: 10.1016/S0076-6879(07)00431-4. Methods Enzymol. 2008. PMID: 18374182

6

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ. Yeh JJ, et al. Among authors: der cj. Mol Cancer Ther. 2009 Apr;8(4):834-43. doi: 10.1158/1535-7163.MCT-08-0972. Mol Cancer Ther. 2009. PMID: 19372556 Free PMC article.

7

Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.

Vigil D, Martin TD, Williams F, Yeh JJ, Campbell SL, Der CJ. Vigil D, et al. Among authors: der cj. J Biol Chem. 2010 Nov 5;285(45):34729-40. doi: 10.1074/jbc.M110.116756. Epub 2010 Aug 27. J Biol Chem. 2010. PMID: 20801877 Free PMC article.

8

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Roberts PJ, et al. Among authors: der cj. J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921461 Review.

9

Are all KRAS mutations created equal?

Stinchcombe TE, Der CJ. Stinchcombe TE, et al. Among authors: der cj. Lancet Oncol. 2011 Aug;12(8):717-8. doi: 10.1016/S1470-2045(11)70200-5. Epub 2011 Jul 22. Lancet Oncol. 2011. PMID: 21782508 No abstract available.

10

Inhibition of Ras for cancer treatment: the search continues.

Baines AT, Xu D, Der CJ. Baines AT, et al. Among authors: der cj. Future Med Chem. 2011 Oct;3(14):1787-808. doi: 10.4155/fmc.11.121. Future Med Chem. 2011. PMID: 22004085 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

394 results

Search Page

Filters